

Jerrold L Boxerman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/465405/publications.pdf>

Version: 2024-02-01

36
papers

4,179
citations

304743

22
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

4147
citing authors

#	ARTICLE	IF	CITATIONS
1	Mr contrast due to intravascular magnetic susceptibility perturbations. <i>Magnetic Resonance in Medicine</i> , 1995, 34, 555-566.	3.0	922
2	Microscopic susceptibility variation and transverse relaxation: Theory and experiment. <i>Magnetic Resonance in Medicine</i> , 1994, 31, 601-610.	3.0	663
3	The intravascular contribution to fmri signal change: monte carlo modeling and diffusion-weighted studies in vivo. <i>Magnetic Resonance in Medicine</i> , 1995, 34, 4-10.	3.0	570
4	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	1.2	346
5	Pitfalls in MR measurement of tissue blood flow with intravascular tracers: Which mean transit time?. <i>Magnetic Resonance in Medicine</i> , 1993, 29, 553-558.	3.0	327
6	Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach. <i>Nature Medicine</i> , 2021, 27, 244-249.	30.7	187
7	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	1.2	131
8	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1262-1275.	1.2	109
9	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. <i>Neuro-Oncology</i> , 2015, 17, 1148-1156.	1.2	108
10	Preoperative MRI Evaluation of Pituitary Macroadenoma: Imaging Features Predictive of Successful Transsphenoidal Surgery. <i>American Journal of Roentgenology</i> , 2010, 195, 720-728.	2.2	91
11	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 228-234.	1.3	77
12	Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. <i>Neuro-Oncology</i> , 2013, 15, 945-954.	1.2	74
13	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	1.2	68
14	Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 467-478.	1.2	67
15	Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis. <i>Clinical Neurology and Neurosurgery</i> , 2014, 125, 125-130.	1.4	55
16	Detecting Large Vessel Occlusion at Multiphase CT Angiography by Using a Deep Convolutional Neural Network. <i>Radiology</i> , 2020, 297, 640-649.	7.3	48
17	Dynamic Susceptibility Contrast MR Imaging in Glioma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 649-670.	1.1	43
18	Is Rolandic epilepsy associated with abnormal findings on cranial MRI?. <i>Epilepsy Research</i> , 2007, 75, 180-185.	1.6	40

#	ARTICLE	IF	CITATIONS
19	A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials. <i>Tomography</i> , 2017, 3, 41-49.	1.8	30
20	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)â€MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1229-1237.	3.4	27
21	Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. <i>Neuro-Oncology</i> , 2018, 20, 1400-1410.	1.2	27
22	Toxoplasmosis versus lymphoma: Cerebral lesion characterization using DSC-MRI revisited. <i>Clinical Neurology and Neurosurgery</i> , 2017, 152, 84-89.	1.4	26
23	Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO). <i>Tomography</i> , 2019, 5, 110-117.	1.8	25
24	An Efficient Computational Approach to Characterize DSC-MRI Signals Arising from Three-Dimensional Heterogeneous Tissue Structures. <i>PLoS ONE</i> , 2014, 9, e84764.	2.5	21
25	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 127-136.	1.2	20
26	Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. <i>Neuro-Oncology</i> , 2021, 23, 314-323.	1.2	18
27	Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study. <i>Radiology</i> , 2019, 290, 467-476.	7.3	15
28	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. <i>Neuro-Oncology</i> , 2021, 23, 189-198.	1.2	11
29	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. <i>Neuro-Oncology</i> , 2022, 24, 1219-1229.	1.2	9
30	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. <i>Neuro-Oncology</i> , 2015, 17, 1538-1539.	1.2	7
31	Myelin water fraction changes in febrile seizures. <i>Clinical Neurology and Neurosurgery</i> , 2018, 175, 61-67.	1.4	7
32	The relationship between cerebral and retinal microbleeds in cerebral amyloid angiopathy (CAA): A pilot study. <i>Journal of the Neurological Sciences</i> , 2021, 423, 117383.	0.6	6
33	Encephalopathy at admission predicts adverse outcomes in patients with SARSâ€CoVâ€2 infection. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 1127-1135.	3.9	3
34	NIMG-25IMPROVED LEAKAGE CORRECTION FOR DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI ESTIMATES OF RELATIVE CEREBRAL BLOOD VOLUME (rCBV) IN HIGH-GRADE GLIOMAS BY ACCOUNTING FOR BIDIRECTIONAL CONTRAST AGENT EXCHANGE. <i>Neuro-Oncology</i> , 2015, 17, v159.1-v159.	1.2	0
35	Bloodâ€brain barrier dysfunction and perioperative neurocognitive disorders: Cognitive Recovery after Elective Surgery (CREATES) study design and methods. <i>Alzheimer's and Dementia</i> , 2020, 16, e039363.	0.8	0
36	Septopreoptic Holoprosencephaly in an Adolescent Presenting with Hypodipsia and Hyponatremia. <i>Journal of Pediatrics</i> , 2021, , .	1.8	0